By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AcelRx Pharmaceuticals 

575 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-216-3500 Fax: 650-216-6500




Company News
AcelRx (ACRX) Appoints Gina Ford As Vice President Commercial Strategy 10/1/2015 6:32:03 AM
AcelRx (ACRX) To Host Analyst & Investor Event On October 2, 2015 9/25/2015 10:12:02 AM
AcelRx (ACRX) Reports That European Commission (EC) Has Granted Marketing Authorization For Zalviso For Treatment Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 9/23/2015 10:32:21 AM
PDL BioPharma (PDLI) Snags a Portion of AcelRx (ACRX)'s Expected Royalties and Commercial Milestones from Zalviso for $65 Million 9/21/2015 6:03:04 AM
AcelRx (ACRX)'s Pain Drug Meets all Endpoints in Pivotal Phase III Study 9/9/2015 5:44:36 AM
AcelRx (ACRX) To Participate At Three Investor Conferences In September 8/26/2015 7:48:52 AM
AcelRx (ACRX) Provides Business Update And Reports Second Quarter And Six Months 2015 Financial Results 8/4/2015 6:19:42 AM
AcelRx (ACRX) To Hold Business Update And Second Quarter Financial Results Conference Call And Webcast On Monday, Aug. 3rd, 2015. 7/29/2015 9:10:00 AM
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015 7:48:32 AM
AcelRx (ACRX) Release: Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain 7/2/2015 7:43:40 AM